clinical trial · NCT02103283
A Phase 1, Open-Label Study of Teprotumumab in Patients With Diabetic Macular Edema (DME)
Amgen·phase1·completed·n = 5
Diabetic Macular EdemaTeprotumumab
brief summary
A Phase 1 Study to evaluate the Safety of teprotumumab in Patients with Diabetic Macular Edema.
started
Oct 1, 2014
primary completion
Aug 1, 2016
completion
Aug 1, 2016
last updated
Jun 25, 2025
detailed description
A Phase 1, Open-Label Safety and Pharmacodynamic Study of RV 001, an Insulin-Like Growth Factor-1 Receptor (IGF-1) Antagonist, Given By IV Infusion in Patients with Diabetic Macular Edema (DME).
official title
Phase 1, Open-Label Safety and Pharmacodynamic Study of RV001, an Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist, Administered by Intravenous (IV) Infusion in Patients With Diabetic Macular Edema (DME)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol